About the Company
for sangamo therapeutics, science is a means to develop new medicines with the potential to transform the lives of patients living with serious genetic diseases. our scientists are leaders in the discovery, research and development of technologies enabling gene-based therapeutic development. currently we are conducting clinical trials, including the first ever in vivo human genome editing studies. to learn more about sangamo, visit the our website at www.sangamo.com.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $SGMO News
Q4 2023 Sangamo Therapeutics Inc Earnings Call
Amy Pooler; Head of Research; Sangamo Therapeutics Inc Nathalie Dubois- Stringfellow; Senior Vice President, Chief Development Officer; Sangamo Therapeutics Inc Luis Santos; Analyst; H.C. Wainwritght ...
Sangamo Therapeutics Announces Data From Novel Proprietary Neurotropic AAV Capsid Demonstrating Industry-leading Blood-brain Barrier Penetration and Brain Tr…
SANGAMO ANNOUNCES DATA FROM PROPRIETARY NEUROTROPIC AAV CAPSID DEMONSTRATING INDUSTRY-LEADING BLOOD-BRAIN BARRIER PENETRATION ...
4 Analysts Assess Sangamo Therapeutics: What You Need To Know
Delving into Sangamo Therapeutics's Background Sangamo Therapeutics Inc is a clinical-stage biotechnology company that translates ground-breaking science into genomic therapies transforming patients' ...
Sangamo Therapeutics files patent for zinc finger fusion protein to treat neurodegenerative diseases
Discover Sangamo Therapeutics' groundbreaking patent for zinc finger fusion proteins targeting alpha-synuclein gene to combat neurodegenerative diseases like Parkinson's and Alzheimer's. Learn about ...
Sangamo: Q4 Earnings Snapshot
BRISBANE, Calif. — BRISBANE, Calif. — Sangamo Therapeutics Inc. (SGMO) on Wednesday reported a loss of $60.3 million in its fourth quarter. On a per-share basis, the Brisbane, California-based company ...
Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results
Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results ...
Sangamo Biosciences Earns Buy Rating on Breakthrough Brain-Targeting Gene Therapy Capsid and Strategic Advancements
TD Cowen analyst Ritu Baral has maintained their bullish stance on SGMO stock, giving a Buy rating yesterday. Ritu Baral has given his Buy ...
With 55% ownership of the shares, Sangamo Therapeutics, Inc. (NASDAQ:SGMO) is heavily dominated by institutional owners
This can be negative in some circumstances. Our information suggests that Sangamo Therapeutics, Inc. insiders own under 1% of ...
Chutes & Ladders—Voyager plucks another Biogen exec for top post
Voyager Therapeutics plucks another Biogen exec, naming Ferguson as new CMO. Pfizer names CSO for anti-infectives research ...
Voyager Therapeutics: A Tortoise With A Shot At Making Gene Therapy Deliver Easier
Voyager Therapeutics investors need to be patient as the biotech targets hard to treat Alzheimer's and Parkinson's. Read why ...
Voyager Therapeutics, Inc.: Voyager Therapeutics Announces Appointment of Toby Ferguson as Chief Medical Officer
Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced the appointment ...
Loading the latest forecasts...